Meeting
2014 ASCO Annual Meeting
Recurrence score and quantitative ER expression to predict in late distant recurrence risk in ER+ BC after 5 years of tamoxifen.
Authors
Norman Wolmark
National Surgical Adjuvant Breast and Bowel Project; The Allegheny Cancer Center at Allegheny General Hospital, Pittsburgh, PA
Norman Wolmark , Eleftherios P Mamounas , Frederick L. Baehner , Steven M. Butler , Gong Tang , Farid Jamshidian , Amy P. Sing , Steven Shak , Soonmyung Paik
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Highlights Session
Session Title
Tumor Biology
Track
Tumor Biology
Sub Track
Genomic and Epigenomic Biomarkers
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 11024)
DOI
10.1200/jco.2014.32.15_suppl.11024
Abstract #
11024
Poster Bd #
13
Abstract Disclosures
Similar Posters
Poster
2013 ASCO Annual Meeting
Prediction of early and late distant recurrence in early-stage breast cancer with Breast Cancer Index.
First Author: Yi Zhang
Poster
2022 ASCO Annual Meeting
Comparison of predicted benefit using RS clin versus observed benefit in a U.S. registry of stage I ER-positive HER2-negative high oncotype DX RS breast cancer.
First Author: Christopher David Walden
Poster
2019 ASCO Annual Meeting
A novel 95-gene signature (Curebest 95GC Breast) that predicts recurrence-risk in patients with ER-positive, HER2-negative, node-negative, early-stage primary invasive breast cancer with an intermediate Oncotype DX Recurrence Score.
First Author: Takeo Fujii